Rosty Raykov Sells 10,000 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Rosty Raykov sold 10,000 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $6.08, for a total value of $60,800.00. Following the completion of the transaction, the director now owns 83,863 shares of the company’s stock, valued at $509,887.04. The trade was a 10.65 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Rosty Raykov also recently made the following trade(s):

• On Thursday, December 5th, Rosty Raykov sold 796 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $6.04, for a total value of $4,807.84.
• On Monday, November 4th, Rosty Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $4.31, for a total value of $10,477.61.

Fennec Pharmaceuticals Stock Down 0.3 %

Shares of NASDAQ:FENC opened at $6.08 on Thursday. The firm has a market capitalization of $167.02 million, a PE ratio of -60.79 and a beta of 0.34. Fennec Pharmaceuticals Inc has a 1 year low of $3.96 and a 1 year high of $11.49. The company has a debt-to-equity ratio of 9.86, a current ratio of 7.80 and a quick ratio of 7.64. The firm’s 50-day moving average is $5.51 and its two-hundred day moving average is $5.52.

Institutional Investors Weigh In On Fennec Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC purchased a new position in Fennec Pharmaceuticals in the 2nd quarter valued at approximately $49,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Fennec Pharmaceuticals in the second quarter valued at $69,000. Franklin Resources Inc. boosted its holdings in Fennec Pharmaceuticals by 18.7% in the third quarter. Franklin Resources Inc. now owns 14,799 shares of the company’s stock valued at $74,000 after purchasing an additional 2,330 shares during the period. Barclays PLC grew its stake in Fennec Pharmaceuticals by 274.3% during the 3rd quarter. Barclays PLC now owns 31,319 shares of the company’s stock worth $157,000 after purchasing an additional 22,951 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in Fennec Pharmaceuticals by 44.7% during the 2nd quarter. Rhumbline Advisers now owns 29,110 shares of the company’s stock worth $178,000 after purchasing an additional 8,987 shares in the last quarter. 55.51% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have weighed in on FENC. Wedbush reaffirmed an “outperform” rating and set a $13.00 target price on shares of Fennec Pharmaceuticals in a research note on Friday, December 20th. Stephens raised shares of Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 18th. Finally, HC Wainwright reissued a “buy” rating and issued a $13.00 target price on shares of Fennec Pharmaceuticals in a research report on Tuesday, December 17th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.